Home
  • Home
  • Companies of Interest
    • Biotech/Specialty Pharma
    • Energy
    • Medical Devices
    • National Defense
    • Service
    • Specialty Chemical
    • Technology
  • Video
  • Dian's Advice
  • About
  • Follow Us
  • Contact Us
Home / Oncolytics Biotech Inc.

Oncolytics Biotech Inc.

Oncolytics Biotech Inc. is focused on the development of oncolytic viruses as a novel and effective approach to cancer treatment. Oncolytics’ lead product, REOLYSIN, is developed from the human reovirus.

Market Data

Download

Fact Sheet
IR Presentation

Recent News

  • Reovirus May be a Novel Approach to Prostate Cancer Treatment
  • Oncolytics Biotech® Inc. Announces 2009 Year End Results
  • Virus Attacks Prostate Cancer
  • What Everyone Should Know When Fighting Cancer
  • Mancow's Morning Madhouse Speaks with Brad Thompson
  • Oncolytics Biotech® Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN® in Head and Neck Cancers
  • Oncolytics Shares Leap For Second Straight Day On High Volume
  • Harmless Virus Could Be an Answer to Cancer
  • Scientists Are "Reolysin" The Power Of Live Biologics To Fight Cancer In Two Recent Studies
  • Oncolytics Biotech® Inc. Reaches Special Protocol Assessment Agreement with FDA on Design of Phase 3 Trial for REOLYSIN®

    Contacts & RSS

    Investor Relations
    Erika Moran

    Public Relations
    Janet Vasquez

    Phone
    212.825.3210
     

     
    Subscribe to Oncolytics Biotech Inc. news, video, and more.

     

    • Home
    • Companies of Interest
      • Biotech/Specialty Pharma
      • Energy
      • Medical Devices
      • National Defense
      • Service
      • Specialty Chemical
      • Technology
    • Video
    • Dian's Advice
    • About
    • Follow Us
    • Contact Us
    Subscribe feed rss
    Copyright © 2010 IRGnews.com. The Investor Relations Group. 11 Stone Street. 3rd Floor, New York, NY. (212) 825-3210